The Cancer Letter

Description

The Cancer Letter, established in 1973, is an acclaimed independent weekly publication that provides in-depth coverage of oncology-related issues. Rooted in Washington DC, this authoritative platform offers award-winning coverage on the development of cancer therapies, drug regulation, legislation, cancer research funding, health care finance, and public health. With a focus on major industry players like the National Cancer Institute, National Institutes of Health, and Food & Drug Administration, The Cancer Letter is a primary source of information for professionals across the healthcare and pharmaceutical sectors.

The Cancer Letter’s readership spans academic institutions, community oncology practices, government agencies, professional associations, health IT and pharmaceutical companies, financial institutions, and advocacy organizations. Its reputation for investigative journalism has led to recognition from major news outlets like The New York Times, The Washington Post, and CNN, and has instigated investigations by several government bodies.

What sets The Cancer Letter apart is its commitment to truth and transparency in the complex world of oncology. Its comprehensive reporting not only educates but contributes to federal action, underscoring its significant role in shaping the oncology landscape. With its finger on the pulse of the industry, The Cancer Letter is an indispensably informative resource for anyone involved in the fight against cancer.